SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-023002
Filing Date
2020-05-07
Accepted
2020-05-07 17:14:44
Documents
60
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ovid-10q_20200331.htm 10-Q 1886206
2 EX-31.1 ovid-ex311_8.htm EX-31.1 21241
3 EX-31.2 ovid-ex312_7.htm EX-31.2 21505
4 EX-32.1 ovid-ex321_6.htm EX-32.1 7551
5 GRAPHIC g1esyhmcjusc000001.jpg GRAPHIC 36561
  Complete submission text file 0001564590-20-023002.txt   5670578

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT ovid-20200331.xml EX-101.INS 1006883
7 XBRL TAXONOMY EXTENSION SCHEMA ovid-20200331.xsd EX-101.SCH 41821
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ovid-20200331_cal.xml EX-101.CAL 33348
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ovid-20200331_def.xml EX-101.DEF 165447
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE ovid-20200331_lab.xml EX-101.LAB 344432
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ovid-20200331_pre.xml EX-101.PRE 267111
Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036
Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38085 | Film No.: 20857600
SIC: 2834 Pharmaceutical Preparations